Atea’s New HCV Combo Aims for Best-in-Class Treatment
Atea reported 98% SVR12 (210/215) in the per‑protocol, treatment‑adherent cohort and 95% SVR12 (245/259) in the per‑protocol, regardless‑of‑adherence cohort...
Pembrolizumab & CNV-NT Combo Study Results in Solid Tumors
Biomed Valley Discoveries reported a 25% confirmed objective response rate (4 of 16 patients) with a median response duration...
Spur Therapeutics Presents Updated Gaucher Gene Therapy Data
Four adults with type 1 Gaucher disease who received a single low dose of avigbagene parvec (FLT201; 4.5e11 vg/kg)...
Arvinas’ PROTAC Degrader Shows Positive Phase 1 Parkinson’s Data
ARV-102 delivered dose-dependent exposure in plasma and CSF, was well tolerated with no serious adverse events or discontinuations, and...
FDA Approves First PNS Device for Chronic Craniofacial Pain
Topline data: In a prospective, multi-center IDE randomized controlled trial for chronic craniofacial pain, 69% of patients on active...
Quantum MS Drug Breakthrough Moves Closer to Phase 2 Trial
Quantum BioPharma has received final 90-day oral toxicity and toxicokinetic reports for Lucid-21-302 (Lucid-MS), positioning the program to support...
Alterity Presents at 2025 Parkinson’s, Movement Disorders
In a randomized, double-blind Phase 2 study of 77 patients with multiple system atrophy (MSA), ATH434 delivered a clinically...
Anavex Drug Delivers Positive Phase 2 Schizophrenia Results
ANAVEX3-71 met its primary endpoint in a placebo-controlled Phase 2 study in adults with schizophrenia on stable antipsychotic therapy,...
Promising VQ-101 Trial Data Offers New Hope for Parkinson’s
VQ-101 delivered more than 70% activation of lysosomal glucocerebrosidase in GBA-Parkinson’s patients after 28 days of once-daily dosing, exceeding...
ALX Oncology Links CD47 to HER2+ Gastric Cancer Outcomes
ALX Oncology will present updated Phase 2 data from ASPEN-06, indicating that tumor CD47 overexpression may predict response to...